Search clinical trials for: Stealth

Total 75 results

University of Massachusetts, Amherst

Completed

The Stealth Pet Obedience Training Study (SPOT)

Physical Activity

United States
Stealth BioTherapeutics Inc.

Completed

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy (MMPOWER)

Mitochondrial Myopathy

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
Stealth BioTherapeutics Inc.

Completed

An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300) (RePOWER)

Primary Mitochondrial Disease

United States, Spain, Germany, Australia, Canada, Denmark, Hungary, Italy, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Plasma Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...

United States
Stealth BioTherapeutics Inc.
Charite University, Berlin, Germany; SCIRENT Clinical Research and Science...

Completed

A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

Chronic Heart Failure

Germany, Serbia
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

A Feasibility Study of a Modular Video Augmentation System for Image-Guided Skull Base Surgery

Feasibility of Video Augmentation System | Value of Video Augmentation Navigation

United States
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

Normal and Impaired Renal Function

United States
Stealth BioTherapeutics Inc.

Completed

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration (SPIOC-101)

Age-related Macular Degeneration | Diabetic Macular Edema

United States
Stealth BioTherapeutics Inc.

Withdrawn

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure

Heart Failure

Bulgaria
Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure

Congestive Heart Failure

Bulgaria
Maastricht University Medical Center

Completed

Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain Tumors (RACING)

Glioblastoma Multiforme

Netherlands, Belgium
Romark Laboratories L.C.

Completed

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C (STEALTHC-2)

Chronic Hepatitis C

United States
Stealth BioTherapeutics Inc.

Completed

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

Healthy Volunteers

United States
Romark Laboratories L.C.

Completed

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients (STEALTHC-3)

Chronic Hepatitis C

United States
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

Healthy

United States
Stealth BioTherapeutics Inc.

Completed

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

Healthy Volunteers

United States
Stealth BioTherapeutics Inc.

Completed

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

Healthy Volunteers

United States
Stealth BioTherapeutics Inc.

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

Healthy

United States
Romark Laboratories L.C.

Completed

Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C (STEALTHC-1)

Chronic Hepatitis C

Egypt
Sequus Pharmaceuticals

Completed

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
Sequus Pharmaceuticals

Completed

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

HIV Infections | Sarcoma, Kaposi

United States

3

Subscribe